Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 404

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 404
---
 of the VEGFR -2protein.

| Mean difference count pool-all minus 
 negative control                     |     | 106 CFU; mean ± SD (N) |     | 107 CFU; mean ± SD (N) |     | Total; mean ± SD (N) |
| Day 0                                |     | 4.5 ± 6.22 (3)         |     | 18.1 ± 17.64 (5)       |     | 13.0 ± 15.46 (8)     |
| Day 21                               |     | 14.5 ± 10.35 (3)       |     | 10.4 ± 17.13 (4)       |     | 12.2 ± 13.68 (7)     |
| Day 35                               |     | 8.4 ± 7.06 (3)         |     | 13.4 ± 15.36 (5)       |     | 11.6 ± 12.48 (8)     |
| Week 12 + 10 days                    |     | -17.5 (2)              |     | 30.6 ± 20.96 (5)       |     | 16.9 ± 30.39 (7)     |
| Week 24 + 10 days                    |     | -2.0 (1)               |     | -4.5 ± 9.57 (4)        |     | -4.0 ± 8.36 (5)      |
| Week 36 + 10 days                    |     | 20.4 (1)               |     | 27.0 (2)               |     | 24.8 ± 4.45 (3)      |
| Week 48 + 10 days                    |     | 29.6 (1)               |     | 28.7 (1)               |     | 29.2 (2)             |

246

Brain Tumor Immunohistochemistry: An analysis of tumor tissue from 8 re -operatedpatients showed a statistically significant increase in CD8 T -cells(immune cells that kill cancer cells) after vaccination with VXM01. Specifically, the mean number of CD8 T -cellsincreased from 159 cells/mm² in the primary tumor to 296 cells/mm² in the recurrent tumor, with a P -valueof 0.